1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Bonesupport Holding AB (publ)

Bonesupport Holding AB (publ)

2B4.F
Bonesupport Holding AB (publ)undefined flagFrankfurt Stock Exchange
20.34
EUR
+0.34
- -
1.34BMarket Cap
Bonesupport Holding AB (publ)
2B4.F
(Frankfurt Stock Exchange)

Recent

price

20.34

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.89
1.34
2.26
3.25
1.9
3
3.06
3.33
5.1
9.1
13.69
17.84
16.14
Revenue per Share
-1.1
-1.29
-2.38
-3.24
-3.46
-3.1
-1.72
-1.34
-1.06
3.77
2.04
2.16
2.25
Basic EPS, GAAP
-1.02
-1.44
-1.8
-2.82
-3.42
-3.24
-1.74
-1.36
-0.78
-0.37
0.91
3.28
3.15
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-10.63
-11.76
-13.73
-18.53
-17.84
-20.64
-19.69
-20.37
-20.22
-15.7
-12.88
-10.43
-11.63
Book Value per Share
-1.05
0.33
0.65
11.19
5.36
2.25
6.6
4.02
4.04
8.21
10.86
12.94
11.88
Tangible Book Value per Share
46
46
46
40
51
52
59
64
64
65
66
66
66
Basic Weighted Avg Shares
41
62
105
129
97
155
181
213
329
591
899
1,175
1,062
Sales/Revenue/Turnover
-105.15
-87.96
-85.84
-75.4
-181.65
-101.45
-53.19
-39.13
-20.56
3.83
16.44
23.63
17.85
Operating Margin (%)
1
1
1
1
2
8
8
8
9
10
11
12
7
Depreciation Expense
-51
-60
-110
-129
-176
-161
-101
-86
-68
245
134
142
148
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
22.52
28.75
16.35
Effective Tax Rate (%)
-124.67
-96.44
-105.35
-99.67
-182.57
-103.6
-56.07
-40.18
-20.73
41.45
14.88
12.1
13.93
Profit Margin (%)
13
14
114
442
269
107
381
247
249
273
478
632
534
Working Capital
63
- -
85
- -
- -
6
6
16
12
13
8
4
6
LT Debt
-44
20
34
451
279
124
399
266
269
545
727
867
797
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.4
24.17
21.82
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-14.79
-19.2
-17.66
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
7
7
7
LT Borrowings
- -
- -
- -
LT Finance Leases
8
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
66
Market Capitalization
25,597
19,424
18,498

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
623
643
694
Cash, Cash Equivalents & STI
227
267
310
Accounts Receivable, Net
196
200
190
Inventories
134
127
132
Total Current Liabilities
144
149
160
Payables & Accruals
- -
- -
- -
ST Debt
7
7
7
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
153.34%
24.64%
19.22%
Free Cash Flow
-12.25%
-39.03%
260.66%
Net Income, GAAP
-44.14%
-106.91%
6.28%
Sales/Revenue/Turnover
37.97%
46.94%
30.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
184
220
238
257
899
2025
284
284
313
- -
1,175
2026
324
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.33
0.42
0.46
0.82
2.04
2025
0.16
0.81
0.67
- -
2.16
2026
0.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Medacta Group S.A. (MEDGF)
Profound Medical Corp. (PRN.TO)
Senzime AB (publ) (SEZI.ST)
ViewRay, Inc. (VRAYQ)
AVITA Medical, Inc. (AVH.AX)
Demant A/S (DEMANT.CO)
Business
Bonesupport Holding AB (publ) (Nasdaq Stockholm: BONEX; FWB: 2B4.F) is a Sweden-based orthobiologics company that develops and commercializes innovative injectable bioceramic bone graft substitutes based on the patented CERAMENT technology platform, which remodels to host bone in six to twelve months and elutes pharmaceuticals to promote healing. The company's core products include CERAMENT BVF for filling bone voids and surgical augmentation; CERAMENT G, a gentamicin-loaded variant for treating bone and joint infections such as chronic osteomyelitis; CERAMENT V, a vancomycin-eluting product for infection management; and CERAMENT G in Spine, under development for spinal procedures, with recruitment of specialized distributors underway. These synthetic, radiopaque, osteoconductive products address fractures and bone voids caused by trauma, infection, disease, revision arthroplasty, diabetic foot complications, and orthopedic surgeries, serving orthopedic surgeons, trauma specialists, and infection management clinicians. Founded in 1999 and headquartered at Scheelevägen 19, Ideon Science Park, Lund, Sweden, Bonesupport operates primarily in two segments: North America, which drives the majority of sales growth, and Europe & Rest of World, with commercial availability in the United States, Europe, India, Malaysia, Oman, Singapore, and additional markets through a network of independent distributors following the termination of its U.S. agreement with Zimmer Biomet in 2018. Recent developments include robust sales growth, with net sales rising 54% to SEK 283.5 million in Q1 2025 (50% at constant exchange rates), led by 63% growth in North America; publication of five-year data from a 105-patient clinical study in January 2025 demonstrating CERAMENT G and V superiority over standard treatments for diabetic foot bone infections, achieving 87.5% survival versus 44.9%; receipt of New Technology Add-on Payment (NTAP) status from U.S. CMS for CERAMENT G; anticipation of FDA decisions on CERAMENT G for open fractures and expanded CMS reimbursements for orthopedic procedures in August 2025; announcement in April 2025 of CEO transition, with Torbjörn Sköld succeeding Emil Billbäck effective September 1, 2025, and Sköld acquiring 15,000 shares in June 2025; and ongoing clinical and regulatory preparations for CERAMENT G in spine indications.